Company: TELO
Filing Date: 2025-09-09
Form Type: 8-K
Source: 0001641172-25-026931
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-09-09
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate
CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy

New
preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene
 - often called the body’s natural “cell cycle brake.” These results build on prior STAT1 data, supporting Telomir-1’s
profile as a potentialfirst-in-class broad-spectrum DNA methylation reset therapy.

Telomir
Pharmaceuticals, Inc. (NASDAQ:TELO) today reported new preclinical cancer data in aggressive human prostate cancer cell models (PC3 xenografts)
showing that Telomir-1 inhibited DNA hypermethylation of CDKN2A

CDKN2A
plays a central role in controlling uninhibited cell growth and initiating programmed cell death, and its silencing is a well-established
hallmark of cancer progression.

Telomir-1
outperformed both Rapamycin and chemotherapy STAT1

Together,
the STAT1 and CDKN2A results demonstrate Telomir-1’s ability to reset epigenetic silencing across multiple tumor suppressor pathways.
This dual effect addresses two of cancer’s most fundamental escape mechanisms: unchecked cell proliferation and immune evasion.

Telomir
is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company’s
pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir
moves toward its first IND submission.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                       
  Dated:                 By:                        /s/                
                         Name:                      Erez               
                         Title:                     Chief